Business Context and Reporting Period
This Form 8-K Current Report was filed by AntriaBio, Inc. (now Rezolute, Inc.) on December 7, 2017, covering events occurring on December 6 and 7, 2017. The filing details a strategic partnership, a corporate merger, and a subsequent name change.
Key Financial Metrics and Agreements
- Upfront Payment: $6 million cash payment to XOMA LLC.
- Equity Issuance: Issuance of $12 million worth of common stock to XOMA LLC, contingent on financing activities in 2018.
- Milestone Payments: Potential clinical, regulatory, and annual net sales milestones totaling up to $222 million.
- Royalties: High single-digit to mid-teens percentage on annual net sales of RZ358; low single-digit percentage on sales of other company products.
- Liquidity/Debt: The filing does not provide specific current cash balances, debt levels, or liquidity ratios.
Material Changes
- Asset Acquisition: Acquired exclusive rights to develop and commercialize XOMA 358 (renamed RZ358) for the orphan indication Congenital Hyperinsulinism.
- Corporate Structure: Entered into a parent/subsidiary merger with its wholly-owned subsidiary, Rezolute, Inc., effective December 18, 2017.
- Corporate Identity: The surviving corporation will change its name from AntriaBio, Inc. to Rezolute, Inc., with corresponding changes to its CUSIP number and trading symbol.
Outlook, Risks, and Unusual Items
- Management Commentary: The company assumes full responsibility for development, regulatory, manufacturing, and commercialization of RZ358.
- Unregistered Securities: The stock issuance to XOMA was exempt from registration under Section 4(a)(2) of the Securities Act as a transaction with an accredited investor.
- Regulatory Disclosure: A press release and shareholder letter were issued under Regulation FD; these are furnished but not filed as part of the legal filing.
- Risks: Future financial obligations are significant and contingent on successful development and sales milestones.
Investor Verification Checklist
- Verify the effective date of the name change and the new trading symbol/CUSIP number (expected post-December 18, 2017).
- Confirm the terms of the $12 million stock issuance and its impact on 2018 financing activities.
- Review the specific clinical and regulatory milestones required to trigger the $222 million in potential payments.
- Monitor the company's cash position to ensure it can fund the $6 million upfront payment and future development costs.